Waites Ken B, Talkington Deborah F
Department of Pathology, WP 230, University of Alabama at Birmingham, 619 19th St. South, Birmingham, AL 35249, USA.
Clin Microbiol Rev. 2004 Oct;17(4):697-728, table of contents. doi: 10.1128/CMR.17.4.697-728.2004.
Mycoplasma pneumoniae is a unique bacterium that does not always receive the attention it merits considering the number of illnesses it causes and the degree of morbidity associated with it in both children and adults. Serious infections requiring hospitalization, while rare, occur in both adults and children and may involve multiple organ systems. The severity of disease appears to be related to the degree to which the host immune response reacts to the infection. Extrapulmonary complications involving all of the major organ systems can occur in association with M. pneumoniae infection as a result of direct invasion and/or autoimmune response. The extrapulmonary manifestations are sometimes of greater severity and clinical importance than the primary respiratory infection. Evidence for this organism's contributory role in chronic lung conditions such as asthma is accumulating. Effective management of M. pneumoniae infections can usually be achieved with macrolides, tetracyclines, or fluoroquinolones. As more is learned about the pathogenesis and immune response elicited by M. pneumoniae, improvement in methods for diagnosis and prevention of disease due to this organism may occur.
肺炎支原体是一种独特的细菌,鉴于它所引发疾病的数量以及在儿童和成人中与之相关的发病程度,它并未总能得到应有的关注。需要住院治疗的严重感染虽较为罕见,但在成人和儿童中均会发生,且可能累及多个器官系统。疾病的严重程度似乎与宿主免疫反应对感染的反应程度有关。由于直接侵袭和/或自身免疫反应,肺炎支原体感染可引发涉及所有主要器官系统的肺外并发症。肺外表现有时比原发性呼吸道感染更为严重,且具有更大的临床重要性。这种微生物在诸如哮喘等慢性肺部疾病中所起的促成作用的证据正在不断积累。肺炎支原体感染通常可用大环内酯类、四环素类或氟喹诺酮类药物有效治疗。随着对肺炎支原体引发的发病机制和免疫反应了解得越来越多,针对该微生物所致疾病的诊断和预防方法可能会有所改进。